Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07155668 · ClinicalTrials.gov registry record · Phase 3
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
A Phase 3 study of Thyroid Eye Disease, sponsored by Viridian Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 13
- Study locations
NCT07155668 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Viridian Therapeutics. The registered enrollment target is 87 participants, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (14% lower). The trial reports 13 study locations across 7 states.
The verdict
NCT07155668, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Viridian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
Conditions Studied
Interventions
- DRUG VRDN-003
- DEVICE Autoinjector
Study Locations (13)
Florida
- C&A Clinical Trials Corp - Cape Coral
- Ilumina Medical Research - Kissimmee
- Med-Care Research - Miami
- Continental Clinical Research, llc - Miami
- Hype Clinical Research, LLC - Miami
Michigan
- Fraser Eye Center - Fraser
- Kahana Oculoplastic and Orbital Surgery - Livonia
Texas
- Baylor College of Medicine, Alkek Eye Center - Houston
- Neuro Eye Clinical Trials INC - Houston
California
- United Medical Research Institute - Inglewood
Illinois
- Advanced Quality Medical Research, LLC - Orland Park
Massachusetts
- Ophthalmic Consultants of Boston - East Weymouth
Nevada
- Vector Clinical Trials - Sparks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07155668
The ClinicalTrials.gov registry entry for NCT07155668 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (14% lower). The listed sponsor is Viridian Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which VRDN-003 is the first listed.
NCT07155668 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Florida, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT07155668 about?
NCT07155668 is a clinical study titled "A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)". This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
What is the current status of trial NCT07155668?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2025-07-01. Estimated completion is 2026-11.
What conditions does trial NCT07155668 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT07155668?
The interventions under investigation include: VRDN-003 (DRUG), Autoinjector (DEVICE).
Who is sponsoring clinical trial NCT07155668?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07155668 being conducted?
This trial has 13 study locations across California, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.